A Randomized, Placebo-controlled, Observer-blinded Phase 1 Study to Assess the Safety and Immunogenicity of Two Different Dose Levels of an Alum Adjuvanted Inactivated Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Flavivirus-naïve Adults Aged 18 to 49 Years

Trial Profile

A Randomized, Placebo-controlled, Observer-blinded Phase 1 Study to Assess the Safety and Immunogenicity of Two Different Dose Levels of an Alum Adjuvanted Inactivated Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Flavivirus-naïve Adults Aged 18 to 49 Years

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs ZIKV-VLA1601 (Primary)
  • Indications Zika virus infection
  • Focus Adverse reactions
  • Sponsors Valneva
  • Most Recent Events

    • 29 Mar 2018 According to a Valneva media release, this study will be presented at the 18th World Vaccine Congress.
    • 01 Mar 2018 Last checked against ClinicalTrials.gov record.
    • 26 Feb 2018 Status changed from not yet recruiting to recruiting, according to an Emergent BioSolutions media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top